MTOR and acute myeloid leukemia: Together, our data support the notion that AML stem/progenitor subsets are heterogeneous; that subsets with high expression of CD34 co-express multiple stem cell surface markers and had high basal intracellular signaling; and AKT/mTOR signaling in these subsets was sensitive to SCF stimulation and MLN0128 inhibition.